LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi announced today it will introduce a portfolio of generic contrast media agents in the United States, starting immediately with the launch of ...

April 10, 2008 (Chicago, IL) – The iso-osmolar contrast medium iodixanol (Visipaque, GE Healthcare) did not prevent renal injury in patients undergoing PCI in the CONTRAST study, reported at last week ...

Fresenius Kabi received Health Canada's Notice of Compliance (NOC) approval for Iodixanol injection on December 17 for both intravenous and intra-arterial administration With the launch of Iodixanol ...

CHICAGO -- Patients who underwent abdominal or pelvic CT imaging with a low-osmolar contrast agent reported more discomfort during the exam than patients who received an iso-osmolar agent, researchers ...

HealthDay News — Iodixanol is associated with lower risk for contrast-induced nephropathy (CIN) versus low-osmolar contrast media (LOCM); and among those receiving LOCM, the greatest risk reduction is ...

Please provide your email address to receive an email when new articles are posted on . Eleven patients reported 22 reactions during intradermal testing. Nine of 11 patients displayed cross-reactivity ...

PARIS, France—High-risk patients with moderate renal dysfunction undergoing coronary angiography or percutaneous coronary intervention (PCI) have the same low rates of contrast induced nephropathy ...

Due to COVID-19 related supply-chain disruptions, Iodixanol and other contrast media agents have been in shortage nationwide. Fresenius Kabi announced the launch of Iodixanol Injection, a generic ...

In this issue of the Journal, Aspelin et al. 1 report findings from a prospective, randomized, double-blind trial that compared iodixanol, a third-generation, iso-osmolar, dimeric, nonionic iodinated ...

Iodixanol and other contrast media agents are in shortage across the U.S. due to COVID-19 related supply-chain disruptions. Fresenius Kabi is committed to preventing and mitigating shortages by ...